Contact
searchSearch
HMP Global
Login
Quiz

Vorasidenib for Previously Untreated Patients With Residual or Recurrent Grade 2 IDH-Mutant Glioma

08/19/2025

Related Content

Quiz
Immune Signatures of Survival in High-Grade Glioma
05/01/2026
Results from a translational analysis of patients with high-grade glioma demonstrated that which of the following immune cell population changes distinguished long-term survivors from short-term survivors?
Results from a translational analysis of patients with high-grade glioma demonstrated that which of the following immune cell population changes distinguished long-term survivors from short-term survivors?
Results from a translational...
05/01/2026
Oncology
News
HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma
04/29/2026
Emily Estrada
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study...
04/29/2026
Oncology
News
Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma
03/31/2026
Emily Estrada
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational...
03/31/2026
Oncology
Matthew Cascio, DO
Videos
Treating a Patient With BRAF-Altered Recurrent or Refractory Pediatric Low-Grade Glioma
03/30/2026
Matthew Cascio, DO
Matthew Cascio, DO, University of Florida, Gainesville, Florida shares insights into his treatment course for a case of a 6-year-old patient with BRAF V600E-mutated recurrent or refractory low-grade glioma.
Matthew Cascio, DO, University of Florida, Gainesville, Florida shares insights into his treatment course for a case of a 6-year-old patient with BRAF V600E-mutated recurrent or refractory low-grade glioma.
Matthew Cascio, DO, University...
03/30/2026
Oncology

Recent News

News
BTX-9341 Shows Promising Efficacy, Safety in HR-Positive, HER2-Negative Advanced Breast Cancer
05/15/2026
Emily Estrada
Clinical Summary: Design/Population: The BTX-9341-101 study evaluated BTX-9341 alone or in combination with fulvestrant in heavily pretreated patients with HR-positive, HER2-negative advanced breast cancer.  Key Outcomes:...
Clinical Summary: Design/Population: The BTX-9341-101 study evaluated BTX-9341 alone or in combination with fulvestrant in heavily pretreated patients with HR-positive, HER2-negative advanced breast cancer.  Key Outcomes:...
Clinical...
05/15/2026
Oncology
News
pCR Guided Chemotherapy De-Escalation Shows Promise in HER2-Positive Early Breast Cancer
05/15/2026
Emily Estrada
A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.
A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.
A chemotherapy-free, pCR-guided...
05/15/2026
Oncology
News
Zongertinib Demonstrates Clinical Promise in HER2-Mutated Non-Small Cell Lung Cancer
05/14/2026
Stephanie Holland
First-line treatment with zongertinib showed sustained efficacy in advanced or metastatic HER2-mutated non-small-cell lung cancer, according to results from the phase 1a/1b Beamion LUNG-1 trial.
First-line treatment with zongertinib showed sustained efficacy in advanced or metastatic HER2-mutated non-small-cell lung cancer, according to results from the phase 1a/1b Beamion LUNG-1 trial.
First-line treatment with...
05/14/2026
Oncology
FDA Alerts
FDA Issues Safety Alert on Tazemetostat Following Secondary Malignancy Risk
05/13/2026
Emily Estrada
The FDA issued a safety alert regarding tazemetostat, citing an increased risk of hematologic second primary malignancies observed in the ongoing SYMPHONY-1 trial.
The FDA issued a safety alert regarding tazemetostat, citing an increased risk of hematologic second primary malignancies observed in the ongoing SYMPHONY-1 trial.
The FDA issued a safety alert...
05/13/2026
Oncology
FDA Approval
FDA Approves Sonrotoclax for Patients With Relapsed/Refractory Mantle Cell Lymphoma
05/13/2026
Emily Estrada
Based on results from the BGB-11417-201 trial, the FDA has approved sonrotoclax for previously treated patients with relapsed/refractory mantle cell lymphoma.
Based on results from the BGB-11417-201 trial, the FDA has approved sonrotoclax for previously treated patients with relapsed/refractory mantle cell lymphoma.
Based on results from the...
05/13/2026
Oncology
FDA Approval
FDA Approves Oral Decitabine and Cedazuridine Plus Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
05/13/2026
Janelle Bradley
The FDA granted approval to the first fully oral regimen of decitabine and cedazuridine plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
The FDA granted approval to the first fully oral regimen of decitabine and cedazuridine plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
The FDA granted approval to the...
05/13/2026
Oncology
News
Tucatinib Plus T-DM1 Shows Sustained Disease Control in HER2-Positive Advanced Breast Cancer
05/13/2026
Emily Estrada
Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.
Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.
Final results from the phase 3...
05/13/2026
Oncology
News
Trastuzumab Deruxtecan Plus Paclitaxel, Trastuzumab, and Pertuzumab Improves Residual Cancer Burden in HER2-Positive Early Breast Cancer
05/11/2026
Stephanie Holland
Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...
Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...
Post hoc analysis results from...
05/11/2026
Oncology
News
Sacituzumab Govitecan Plus Trastuzumab Showed Limited Activity After T-DXd in HER2-Positive Metastatic Breast Cancer
05/11/2026
Stephanie Holland
According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
According to results from the...
05/11/2026
Oncology
FDA Approval
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma
05/08/2026
Stephanie Holland
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase...
05/08/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use